|
1
|
Cabibbo G, Enea M, Attanasio M, Bruix J,
Craxì A and Cammà C: A meta-analysis of survival rates of untreated
patients in randomized clinical trials of hepatocellular carcinoma.
Hepatology. 51:1274–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Makuuchi M and Sano K: Surgical treatment
of HCC: Update topics. Updates Surg. 63:67–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Santini D, Pantano F, Riccardi F, Di
Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P,
Marinelli S, et al: Natural history of malignant bone disease in
hepatocellular carcinoma: Final results of a multicenter bone
metastasis survey. PLoS One. 9:e1052682014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi C and Seong J: Predictive factors of
palliative radiotherapy response and survival in patients with
spinal metastases from hepatocellular carcinoma. Gut Liver.
9:94–102. 2015. View Article : Google Scholar :
|
|
5
|
Kim SU, Kim DY, Park JY, Ahn SH, Nah HJ,
Chon CY and Han KH: Hepatocellular carcinoma presenting with bone
metastasis: Clinical characteristics and prognostic factors. J
Cancer Res Clin Oncol. 134:1377–1384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hang LH, Li SN, Luo H, Shu WW, Mao ZM,
Chen YF, Shi LL and Shao DH: Connexin 43 mediates CXCL12 production
from spinal dorsal horn to maintain bone cancer pain in rats.
Neurochem Res. 41:1200–1208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Obenauf AC and Massagué J: Surviving at a
distance: Organ-specific metastasis. Trends Cancer. 1:76–91. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esposito M and Kang Y: Targeting
tumor-stromal interactions in bone metastasis. Pharmacol Ther.
141:222–233. 2014. View Article : Google Scholar :
|
|
9
|
Yousefi M, Nosrati R, Salmaninejad A,
Dehghani S, Shahryari A and Saberi A: Organ-specific metastasis of
breast cancer: Molecular and cellular mechanisms underlying lung
metastasis. Cell Oncol (Dordr). 41:123–140. 2018. View Article : Google Scholar
|
|
10
|
Hida K, Maishi N, Sakurai Y, Hida Y and
Harashima H: Heterogeneity of tumor endothelial cells and drug
delivery. Adv Drug Deliv Rev. 99:140–147. 2016. View Article : Google Scholar
|
|
11
|
Colmone A and Sipkins DA: Beyond
angiogenesis: The role of endothelium in the bone marrow vascular
niche. Transl Res. 151:1–9. 2008. View Article : Google Scholar
|
|
12
|
Singh S, Singh R, Sharma PK, Singh UP, Rai
SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE and Lillard JW
Jr: Serum CXCL13 positively correlates with prostatic disease,
prostate-specific antigen and mediates prostate cancer cell
invasion, integrin clustering and cell adhesion. Cancer Lett.
283:29–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kopp HG, Avecilla ST, Hooper AT and Rafii
S: The bone marrow vascular niche: Home of HSC differentiation and
mobilization. Physiology (Bethesda). 20:349–356. 2005.
|
|
14
|
Li WM, Huang WQ, Huang YH, Jiang DZ and
Wang QR: Positive and negative hematopoietic cytokines produced by
bone marrow endothelial cells. Cytokine. 12:1017–1023. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bade-Döding C, Göttmann W, Baigger A,
Farren M, Lee KP, Blasczyk R and Huyton T: Autocrine GM-CSF
transcription in the leukemic progenitor cell line KG1a is mediated
by the transcription factor ETS1 and is negatively regulated
through SECTM1 mediated ligation of CD7. Biochim Biophys Acta.
1840:1004–1013. 2014. View Article : Google Scholar
|
|
16
|
Lavi N, Kessler O, Ziv K, Nir-Zvi I,
Mumblat Y, Eiza N, Paran Y, Brenner B, Vadasz Z and Neufeld G:
Semaphorin-3A inhibits multiple myeloma progression in a mouse
model. Carcinogenesis. 39:1283–1291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamanuzzi A, Saltarella I, Ferrucci A, Ria
R, Ruggieri S, Racanelli V, Rao L, Annese T, Nico B, Vacca A, et
al: Role of erythropoietin in the angiogenic activity of bone
marrow endothelial cells of MGUS and multiple myeloma patients.
Oncotarget. 7:14510–14521. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Griffith JW, Sokol CL and Luster AD:
Chemokines and chemokine receptors: Positioning cells for host
defense and immunity. Annu Rev Immunol. 32:659–702. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong HS, Jaumouillé V, Heit B, Doodnauth
SA, Patel S, Huang YW, Grinstein S and Robinson LA: Cytoskeletal
confinement of CX3CL1 limits its susceptibility to proteolytic
cleavage by ADAM10. Mol Biol Cell. 25:3884–3899. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang J, Xiao L, Cui R, Li D, Zheng X, Zhu
L, Sun H, Pan Y, Du Y and Yu X: CX3CL1 increases invasiveness and
metastasis by promoting epithelial-to-mesenchymal transition
through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent
prostate cancer cells. Oncol Rep. 35:1153–1162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei LM, Cao S, Yu WD, Liu YL and Wang JT:
Overexpression of CX3CR1 is associated with cellular metastasis,
proliferation and survival in gastric cancer. Oncol Rep.
33:615–624. 2015. View Article : Google Scholar
|
|
23
|
Tardáguila M, Mira E, García-Cabezas MA,
Feijoo AM, Quintela-Fandino M, Azcoitia I, Lira SA and Mañes S:
CX3CL1 promotes breast cancer via transactivation of the EGF
pathway. Cancer Res. 73:4461–4473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao X, Qi L, Chen X, Du J, Zhang Z and Liu
S: Expression of CX3CR1 associates with cellular migration,
metastasis, and prognosis in human clear cell renal cell carcinoma.
Urol Oncol. 32:162–170. 2014. View Article : Google Scholar
|
|
25
|
Zheng J, Yang M, Shao J, Miao Y, Han J and
Du J: Chemokine receptor CX3CR1 contributes to macrophage survival
in tumor metastasis. Mol Cancer. 12:1412013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liang Y, Yi L, Liu P, Jiang L, Wang H, Hu
A, Sun C and Dong J: CX3CL1 involves in breast cancer metastasizing
to the spine via the Src/FAK signaling pathway. J Cancer.
9:3603–3612. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu P, Liang Y, Jiang L, Wang H, Wang S
and Dong J: CX3CL1/fractalkine enhances prostate cancer spinal
metastasis by activating the Src/FAK pathway. Int J Oncol.
53:1544–1556. 2018.PubMed/NCBI
|
|
28
|
Wang R, Yu Z, Chen F, Xu H, Shen S, Chen
W, Chen L, Su Q, Zhang L, Bi J, et al: miR-300 regulates the
epithelial-mesenchymal transition and invasion of hepatocellular
carcinoma by targeting the FAK/PI3K/AKT signaling pathway. Biomed
Pharmacother. 103:1632–1642. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen JS, Huang XH, Wang Q, Chen XL, Fu XH,
Tan HX, Zhang LJ, Li W and Bi J: FAK is involved in invasion and
metastasis of hepatocellular carcinoma. Clin Exp Metastasis.
27:71–82. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li D, Zhang Y, Zhang H, Zhan C, Li X, Ba
T, Qiu Z, E F, Lv G, Zou C, et al: CADM2, as a new target of
miR-10b, promotes tumor metastasis through FAK/AKT pathway in
hepatocellular carcinoma. J Exp Clin Cancer Res. 37:462018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang YL, Xing X, Cai LB, Zhu L, Yang XM,
Wang YH, Yang Q, Nie HZ, Zhang ZG, Li J, et al: Integrin α9
suppresses hepatocellular carcinoma metastasis by Rho GTPase
signaling. J Immunol Res. 2018:46025702018. View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
34
|
Beyer H: The Wilcoxon, Mann and Whitney
U-test - a distribution-independent statistical procedure for the
comparison of 2 independent random samples. Z Arztl Fortbild
(Jena). 82:871–873. 1988.In German.
|
|
35
|
Stout MC, Narayan S, Pillet ES, Salvino JM
and Campbell PM: Inhibition of CX3CR1 reduces cell motility and
viability in pancreatic adenocarcinoma epithelial cells. Biochem
Biophys Res Commun. 495:2264–2269. 2018. View Article : Google Scholar
|
|
36
|
Ishida Y, Kimura A, Nosaka M, Kuninaka Y,
Hemmi H, Sasaki I, Kaisho T, Mukaida N and Kondo T: Essential
involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced
pulmonary fibrosis via regulation of fibrocyte and M2 macrophage
migration. Sci Rep. 7:168332017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jamieson-Gladney WL, Zhang Y, Fong AM,
Meucci O and Fatatis A: The chemokine receptor CX(3)CR1 is directly
involved in the arrest of breast cancer cells to the skeleton.
Breast Cancer Res. 13:R912011. View Article : Google Scholar
|
|
38
|
Longo V, Brunetti O, D'Oronzo S, Ostuni C,
Gatti P and Silvestris F: Bone metastases in hepatocellular
carcinoma: An emerging issue. Cancer Metastasis Rev. 33:333–342.
2014. View Article : Google Scholar
|
|
39
|
Pascual J and Turner NC: Targeting the
PI3-kinase pathway in triple-negative breast cancer. Ann Oncol.
30:1051–1060. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang GX, Wang Y, Su J, Zhou P, Li B, Yin
LJ and Lu J: Up-regulation of Rho-associated kinase 1/2 by
glucocorticoids promotes migration, invasion and metastasis of
melanoma. Cancer Lett. 410:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song LJ, Liu Q, Meng XR, Li ShL, Wang LX,
Fan QX and Xuan XY: DLC-1 is an independent prognostic marker and
potential therapeutic target in hepatocellular cancer. Diagn
Pathol. 11:192016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Samarin J, Laketa V, Malz M, Roessler S,
Stein I, Horwitz E, Singer S, Dimou E, Cigliano A, Bissinger M, et
al: PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream
element binding proteins in hepatocellular carcinoma cells.
Hepatology. 63:813–826. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng Y, Chen X, Ye L, Zhang Y, Liang J,
Liu W, Zhou B, Zheng S, Huang Y, Chen G, et al: The prognostic
significance of NEK2 in hepatocellular carcinoma: Evidence from a
meta-analysis and retrospective cohort study. Cell Physiol Biochem.
51:2746–2759. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Wang W, Wang Y, Huang X, Zhang Z,
Chen B, Xie W, Li S, Shen S and Peng B: NEK2 promotes
hepatocellular carcinoma migration and invasion through modulation
of the epithelial-mesenchymal transition. Oncol Rep. 39:1023–1033.
2018.PubMed/NCBI
|
|
45
|
De Sanctis F, Ugel S, Facciponte J and
Facciabene A: The dark side of tumor-associated endothelial cells.
Semin Immunol. 35:35–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bergmeier W, Piffath CL, Cheng G, Dole VS,
Zhang Y, von Andrian UH and Wagner DD: Tumor necrosis
factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding
from platelets in vitro and in vivo. Circ Res. 95:677–683. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Saad MI, Alhayyani S, McLeod L, Yu L,
Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, et
al: ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK
axis in KRAS-addicted lung cancer. EMBO Mol Med. 11:112019.
View Article : Google Scholar
|
|
48
|
Zhu H, Shao Q, Sun X, Deng Z, Yuan X, Zhou
X and Ding Y: Bone marrow cells: Important role on
neovascularization of hepatocellular carcinoma. J Gastroenterol
Hepatol. 27:1241–1251. 2012. View Article : Google Scholar
|
|
49
|
Pan Q, Wang L, Sun HC, Liu YK, Ye SL and
Tang ZY: Transcription factor activity profile of human
hepatocellular carcinoma cell lines with different metastatic
potentials. Zhonghua Gan Zang Bing Za Zhi. 14:37–40. 2006.In
Chinese. PubMed/NCBI
|
|
50
|
Kusumbe AP, Ramasamy SK and Adams RH:
Coupling of angiogenesis and osteogenesis by a specific vessel
subtype in bone. Nature. 507:323–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu W, Jiang L, Bian C, Liang Y, Xing R,
Yishakea M and Dong J: Role of CX3CL1 in diseases. Arch Immunol
Ther Exp (Warsz). 64:371–383. 2016. View Article : Google Scholar
|
|
52
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.PubMed/NCBI
|
|
53
|
Aligayer H, Boyd DD, Heiss MM, Abdalla EK,
Curley SA and Gallick GE: Activation of Src kinase in primary
colorectal carcinoma: An indicator of poor clinical prognosis.
Cancer. 94:344–351. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Van Slambrouck S, Grijelmo C, De Wever O,
Bruyneel E, Emami S, Gespach C and Steelant WF: Activation of the
FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by
alpha1-integrins during colon cancer cell invasion. Int J Oncol.
31:1501–1508. 2007.PubMed/NCBI
|
|
55
|
Yoon H, Dehart JP, Murphy JM and Lim ST:
Understanding the roles of FAK in cancer: Inhibitors, genetic
models, and new insights. J Histochem Cytochem. 63:114–128. 2015.
View Article : Google Scholar :
|
|
56
|
Hu YL, Lu S, Szeto KW, Sun J, Wang Y,
Lasheras JC and Chien S: FAK and paxillin dynamics at focal
adhesions in the protrusions of migrating cells. Sci Rep.
4:60242014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sulzmaier FJ, Jean C and Schlaepfer DD:
FAK in cancer: Mechanistic findings and clinical applications. Nat
Rev Cancer. 14:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jeong KY: Inhibiting focal adhesion
kinase: A potential target for enhancing therapeutic efficacy in
colorectal cancer therapy. World J Gastrointest Oncol. 10:290–292.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Golubovskaya VM: Focal adhesion kinase as
a cancer therapy target. Anticancer Agents Med Chem. 10:735–741.
2010. View Article : Google Scholar
|
|
60
|
Schmidt TT, Tauseef M, Yue L, Bonini MG,
Gothert J, Shen TL, Guan JL, Predescu S, Sadikot R and Mehta D:
Conditional deletion of FAK in mice endothelium disrupts lung
vascular barrier function due to destabilization of RhoA and Rac1
activities. Am J Physiol Lung Cell Mol Physiol. 305:L291–L300.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Luo J, Yao JF, Deng XF, Zheng XD, Jia M,
Wang YQ, Huang Y and Zhu JH: 14, 15-EET induces breast cancer cell
EMT and cisplatin resistance by up-regulating integrin αvβ3 and
activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res.
37:232018. View Article : Google Scholar
|
|
63
|
Zheng H, Yang Y, Hong YG, Wang MC, Yuan
SX, Wang ZG, Bi FR, Hao LQ, Yan HL and Zhou WP: Tropomodulin 3
modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma
metastasis. Mol Carcinog. 58:1897–1907. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Neal CP, Fry AM, Moreman C, McGregor A,
Garcea G, Berry DP and Manson MM: Overexpression of the Nek2 kinase
in colorectal cancer correlates with beta-catenin relocalization
and shortened cancer-specific survival. J Surg Oncol. 110:828–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Akino T, Hida K, Hida Y, Tsuchiya K,
Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T,
et al: Cytogenetic abnormalities of tumor-associated endothelial
cells in human malignant tumors. Am J Pathol. 175:2657–2667. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Montes de Oca-B P: Ectdomain shedding and
regulated intracellular proteolysis in the central nervous system.
Cent Nerv Syst Agents Med Chem. 10:337–359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Dreymueller D, Martin C, Kogel T,
Pruessmeyer J, Hess FM, Horiuchi K, Uhlig S and Ludwig A: Lung
endothelial ADAM17 regulates the acute inflammatory response to
lipopolysaccharide. EMBO Mol Med. 4:412–423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tsou CL, Haskell CA and Charo IF: Tumor
necrosis factor-alpha-converting enzyme mediates the inducible
cleavage of fractalkine. J Biol Chem. 276:44622–44626. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen
M and Ren H: Gene therapy with CX3CL1/Fractalkine induces antitumor
immunity to regress effectively mouse hepatocellular carcinoma.
Gene Ther. 14:1226–1234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Rades D, Stalpers LJ, Hulshof MC, Borgmann
K, Karstens JH, Koning CC and Alberti W: Comparison of 1×8 Gy and
10×3 Gy for functional outcome in patients with metastatic spinal
cord compression. Int J Radiat Oncol Biol Phys. 62:514–518. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li Z, Wu T, Zheng B and Chen L:
Individualized precision treatment: Targeting TAM in HCC. Cancer
Lett. 458:86–91. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Atanasov G, Dino K, Schierle K, Dietel C,
Aust G, Pratschke J, Seehofer D, Schmelzle M and Hau HM:
Immunologic cellular characteristics of the tumour microenvironment
of hepatocellular carcinoma drive patient outcomes. World J Surg
Oncol. 17:972019. View Article : Google Scholar : PubMed/NCBI
|
